This study is an randomized double-blind placebo-controlled study to evaluate the efficacy
and the safety of oral KHK4577 for 6 weeks in patients with atopic dermatitis.
Pharmacokinetics of KHK4577 will also be assessed.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.